摘要:
Microwells, which are open on both sides and are arranged two-dimensionally in a microwell matrix (4), are hermetically closed by pressure on both sides using plugs (6) covered with a sealing sheet (11). A layer of elastic material (9), which is arranged between the plug (6) and the sealing sheet (11), guarantees uniform pressure on all the microwells of a microwell matrix (4) which is loosely held by a frame structure (1). Continuous peripheral elevations (2), which protrude in both directions at right angles to the plane of the microwell matrix (4), ensure that the deformable thin layer of elastic material (9) does not escape sideways between the plug (6) and the microwell matrix (4) during the pressing process. A plurality of microwell matrices (4) are held simultaneously by the frame structure (1) and are hermetically closed by a corresponding number of allocated plugs (6), which are fastened to a base plate (7) and a cover plate (8), respectively.
摘要:
The invention relates to a sampling device (1) for a microreaction system (3), comprising an outlet (4) and a suction line opening (9) which is arranged next to the outlet (4). A depression can be produced in the suction line (9) for the suction of the substances (13) leaving the outlet (4). The outlet (4) is embodied as a capillary and can be positioned in relation to the opening of the suction line (9). The outlet (4) is surrounded by a housing (6) comprising a discharge outlet (14) for the substances (13) leaving the outlet (4), and a through-opening (8) for the suction line (9). Said suction line (9) opens up into a collecting tank (10) that is connected to a vacuum line (12) by means of an electrovalve (1).
摘要:
Compounds of the formula I wherein R1, R2 and R3 have the meanings defined herein, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, ischaemias, inflammations, arteriosclerosis and osteolytic disorders.
摘要:
Novel oxazolidinone derivatives of the formula I ##STR1## in which R.sup.1 is a phenyl radical which is unsubstituted or is monosubstituted by CN, H.sub.2 N--CH.sub.2 --, A.sub.2 N--CH.sub.2 --, H.sub.2 N--C(.dbd.NH)--, H.sub.2 N--C(.dbd.NH)--NH--, H.sub.2 N--C(.dbd.NH)--NH--CH.sub.2 --, HO--NH--C(.dbd.NH)-- or HO--NH--C(.dbd.NH)--NH--,X is O, S, SO, SO.sub.2, --NH-- or --NA--,B is ##STR2## A is alkyl having from 1 to 6 C atoms, R.sup.2 is H, A, Li, Na, K, NH.sub.4 or benzyl,R.sup.3 is H or (CH.sub.2).sub.n --COOR.sup.2,E is, in each case independently of each other, CH or N,Q is O, S or NH,m is 1, 2 or 3, andn is 0, 1, 2 or 3,and physiologically compatible salts thereof are provided, which inhibit the binding of fibrinogen to the corresponding receptor and can be used for treating thrombosis, stroke, cardiac infarction, inflammations, arteriosclerosis, osteoporosis and also tumors.
摘要:
The invention relates to compounds of the formula (I), in which R1, R2, R3, R4, Y and A have the meanings indicated, and to processes for the preparation thereof and to the use thereof for the preparation of medicaments.
摘要:
The invention relates to novel compounds of formula (I), wherein R, R1, R2, R3, n and p have the meaning defined in claim 1. Compounds are inhibitors of clotting factor Xa and can be used for the prophylaxis and/or therapy of thrombo-embolic disorders.
摘要:
Compounds of the formula I in which R1, R2 and R3 have the stated meanings, and their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be used for the treatment of thromboses, osteoporoses, oncoses, stroke, myocardial infarct, ischemias, inflammations, arteriosclerosis and osteolytic disorders.
摘要:
Compounds of the formula I ##STR1## wherein R.sup.1 and Y have the meanings indicated herein, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, inflammations, arteriosclerosis and osteolytic disorders.
摘要:
Novel oxazolidinone derivatives of the formula I ##STR1## in which R.sup.1 is a phenyl radical which is unsubstituted or is monosubstituted by CN, H.sub.2 N--CH.sub.2 --, A.sub.2 N--CH.sub.2 --, H.sub.2 N--C(.dbd.NH)--, H.sub.2 N--C(.dbd.NH)--NH--, H.sub.2 N--C(.dbd.NH)--NH--CH.sub.2 --, HO--NH--C(.dbd.NH)-- or HO--NH--C(.dbd.NH)--NH--,X is O, S, SO, SO.sub.2, --NH-- or --NA--,B is ##STR2## or ##STR3## A is alkyl having from 1 to 6 C atoms,R.sup.2 is H, A, Li, Na, K, NH.sub.4 or benzyl,R.sup.3 is H or (CH.sub.2).sub.n --COOR.sup.2,E is, in each case independently of each other, CH or N,Q is O, S or NH,m is 1, 2 or 3, andn is 0, 1, 2 or 3,and physiologically compatible salts thereof are provided, which inhibit the binding of fibrinogen to the corresponding receptor and can be used for treating thrombosis, stroke, cardiac infarction, inflammations, arteriosclerosis, osteoporosis and also tumors.